Cargando…

Illness progression in chronic fatigue syndrome: a shifting immune baseline

BACKGROUND: Validation of biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) across data sets has proven disappointing. As immune signature may be affected by many factors, our objective was to explore the shift in discriminatory cytokines across ME/CFS subjects separated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Lindsey, Broderick, Gordon, Taylor, Renee, Fernandes, Henrique, Harvey, Jeanna, Barnes, Zachary, Smylie, AnneLiese, Collado, Fanny, Balbin, Elizabeth G., Katz, Ben Z., Klimas, Nancy G., Fletcher, Mary Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785654/
https://www.ncbi.nlm.nih.gov/pubmed/26965484
http://dx.doi.org/10.1186/s12865-016-0142-3
_version_ 1782420440405245952
author Russell, Lindsey
Broderick, Gordon
Taylor, Renee
Fernandes, Henrique
Harvey, Jeanna
Barnes, Zachary
Smylie, AnneLiese
Collado, Fanny
Balbin, Elizabeth G.
Katz, Ben Z.
Klimas, Nancy G.
Fletcher, Mary Ann
author_facet Russell, Lindsey
Broderick, Gordon
Taylor, Renee
Fernandes, Henrique
Harvey, Jeanna
Barnes, Zachary
Smylie, AnneLiese
Collado, Fanny
Balbin, Elizabeth G.
Katz, Ben Z.
Klimas, Nancy G.
Fletcher, Mary Ann
author_sort Russell, Lindsey
collection PubMed
description BACKGROUND: Validation of biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) across data sets has proven disappointing. As immune signature may be affected by many factors, our objective was to explore the shift in discriminatory cytokines across ME/CFS subjects separated by duration of illness. METHODS: Cytokine expression collected at rest across multiple studies for female ME/CFS subjects (i) 18 years or younger, ill for 2 years or less (n = 18), (ii) 18–50 years of age, ill for 7 years (n = 22), and (iii) age 50 years or older (n = 28), ill for 11 years on average. Control subjects were matched for age and body mass index (BMI). Data describing the levels of 16 cytokines using a chemiluminescent assay was used to support the identification of separate linear classification models for each subgroup. In order to isolate the effects of duration of illness alone, cytokines that changed significantly with age in the healthy control subjects were excluded a priori. RESULTS: Optimal selection of cytokines in each group resulted in subsets of IL-1α, 6, 8, 15 and TNFα. Common to any 2 of 3 groups were IL-1α, 6 and 8. Setting these 3 markers as a triple screen and adjusting their contribution according to illness duration sub-groups produced ME/CFS classification accuracies of 75–88 %. The contribution of IL-1α, higher in recently ill adolescent ME/CFS subjects was progressively less important with duration. While high levels of IL-8 screened positive for ME/CFS in the recently afflicted, the opposite was true for subjects ill for more than 2 years. Similarly, while low levels of IL-6 suggested early ME/CFS, the reverse was true in subjects over 18 years of age ill for more than 2 years. CONCLUSIONS: These preliminary results suggest that IL-1α, 6 and 8 adjusted for illness duration may serve as robust biomarkers, independent of age, in screening for ME/CFS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12865-016-0142-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4785654
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47856542016-03-11 Illness progression in chronic fatigue syndrome: a shifting immune baseline Russell, Lindsey Broderick, Gordon Taylor, Renee Fernandes, Henrique Harvey, Jeanna Barnes, Zachary Smylie, AnneLiese Collado, Fanny Balbin, Elizabeth G. Katz, Ben Z. Klimas, Nancy G. Fletcher, Mary Ann BMC Immunol Research Article BACKGROUND: Validation of biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) across data sets has proven disappointing. As immune signature may be affected by many factors, our objective was to explore the shift in discriminatory cytokines across ME/CFS subjects separated by duration of illness. METHODS: Cytokine expression collected at rest across multiple studies for female ME/CFS subjects (i) 18 years or younger, ill for 2 years or less (n = 18), (ii) 18–50 years of age, ill for 7 years (n = 22), and (iii) age 50 years or older (n = 28), ill for 11 years on average. Control subjects were matched for age and body mass index (BMI). Data describing the levels of 16 cytokines using a chemiluminescent assay was used to support the identification of separate linear classification models for each subgroup. In order to isolate the effects of duration of illness alone, cytokines that changed significantly with age in the healthy control subjects were excluded a priori. RESULTS: Optimal selection of cytokines in each group resulted in subsets of IL-1α, 6, 8, 15 and TNFα. Common to any 2 of 3 groups were IL-1α, 6 and 8. Setting these 3 markers as a triple screen and adjusting their contribution according to illness duration sub-groups produced ME/CFS classification accuracies of 75–88 %. The contribution of IL-1α, higher in recently ill adolescent ME/CFS subjects was progressively less important with duration. While high levels of IL-8 screened positive for ME/CFS in the recently afflicted, the opposite was true for subjects ill for more than 2 years. Similarly, while low levels of IL-6 suggested early ME/CFS, the reverse was true in subjects over 18 years of age ill for more than 2 years. CONCLUSIONS: These preliminary results suggest that IL-1α, 6 and 8 adjusted for illness duration may serve as robust biomarkers, independent of age, in screening for ME/CFS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12865-016-0142-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-10 /pmc/articles/PMC4785654/ /pubmed/26965484 http://dx.doi.org/10.1186/s12865-016-0142-3 Text en © Russell et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Russell, Lindsey
Broderick, Gordon
Taylor, Renee
Fernandes, Henrique
Harvey, Jeanna
Barnes, Zachary
Smylie, AnneLiese
Collado, Fanny
Balbin, Elizabeth G.
Katz, Ben Z.
Klimas, Nancy G.
Fletcher, Mary Ann
Illness progression in chronic fatigue syndrome: a shifting immune baseline
title Illness progression in chronic fatigue syndrome: a shifting immune baseline
title_full Illness progression in chronic fatigue syndrome: a shifting immune baseline
title_fullStr Illness progression in chronic fatigue syndrome: a shifting immune baseline
title_full_unstemmed Illness progression in chronic fatigue syndrome: a shifting immune baseline
title_short Illness progression in chronic fatigue syndrome: a shifting immune baseline
title_sort illness progression in chronic fatigue syndrome: a shifting immune baseline
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785654/
https://www.ncbi.nlm.nih.gov/pubmed/26965484
http://dx.doi.org/10.1186/s12865-016-0142-3
work_keys_str_mv AT russelllindsey illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT broderickgordon illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT taylorrenee illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT fernandeshenrique illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT harveyjeanna illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT barneszachary illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT smylieanneliese illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT colladofanny illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT balbinelizabethg illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT katzbenz illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT klimasnancyg illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline
AT fletchermaryann illnessprogressioninchronicfatiguesyndromeashiftingimmunebaseline